Actively Recruiting
Evaluating 18FPSMA-1007 PETCT Imaging Accuracy in Newly Diagnosed High-Risk Prostate Cancer Patients
Led by ABX advanced biochemical compounds GmbH · Updated on 2026-11-04
434
Participants Needed
19
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the diagnostic accuracy of 18FPSMA-1007 PETCT imaging in men newly diagnosed with high-risk or very-high-risk prostate cancer. This phase 3 study focuses on patients with biopsy-confirmed, clinically localized prostate adenocarcinoma who are candidates for curative prostatectomy with extended pelvic lymph node dissection. The goal is to compare PETCT results with tissue histology to assess how well this imaging detects pelvic nodal disease. Participants will receive a single intravenous dose of 18FPSMA-1007, a diagnostic radiopharmaceutical, followed by a PET scan. Prior to this, they must have completed conventional imaging methods like CT or MRI and, if needed, a bone scan. This study includes only one group undergoing this imaging procedure to evaluate its diagnostic performance. During the study, participants will undergo PETCT imaging, and results will be compared with histology obtained 6 to 8 weeks after surgery to measure sensitivity and specificity. Researchers will monitor eligibility, adverse reactions, and adherence to the imaging protocol. The total participation duration extends until after surgery and histological analysis, with the primary outcome measured several weeks post-surgery.
CONDITIONS
Brief Title
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
Research Team
A
Alexander Hoepping, Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here